Leukotriene B4 amplifies NF-κB activation in mouse macrophages by reducing SOCS1 inhibition of MyD88 expression

Journal of Clinical Investigation

Volumn 121, Issue 2, 2011, Pages 671-682

  Serezani, Carlos H ^a   Lewis, Casey ^a   Jancar, Sonia ^b   Peters Golden, Marc ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEUKOTRIENE B4; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 88; NITRIC OXIDE; RANTES; SMALL INTERFERING RNA; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; JAK2 PROTEIN, MOUSE; JANUS KINASE 2; SOCS1 PROTEIN, MOUSE; STAT1 PROTEIN, MOUSE; SUPPRESSOR OF CYTOKINE SIGNALING;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; C57BL MOUSE; CYTOLOGY; GENE SILENCING; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MOUSE MUTANT; RNA INTERFERENCE;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; CHEMOKINE CCL5; FEMALE; GENE SILENCING; IMMUNITY, INNATE; INTERLEUKIN-6; JANUS KINASE 2; LEUKOTRIENE B4; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 79551526507     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI43302     Document Type: Article

References (54)

1. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science. 2010;327(5963):291-295.
2. Takeuchi O, Akira S. MyD88 as a bottle neck in Toll/ IL-1 signaling. Curr Top Microbiol Immunol. 2002;270:155-167.
3. Bezbradica JS, Medzhitov R. Integration of cytokine and heterologous receptor signaling pathways. Nat Immunol. 2009;10(4):333-339.
4. Janssens S, Beyaert R. A universal role for MyD88 in TLR/IL-1R-mediated signaling. Trends Biochem Sci. 2002;27(9):474-482.
5. Michelsen KS, Arditi M. Toll-like receptor signaling and atherosclerosis. Curr Opin Hematol. 2006;13(3):163-168.
6. O'Neill LA. Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. Curr Opin Pharmacol. 2003;3(4):396-403.
7. Aksentijevich I, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med. 2009;360(23):2426-2437.
8. Lord KA, Hoffman-Liebermann B, Liebermann DA. Nucleotide sequence and expression of a cDNA encoding MyD88, a novel myeloid differentiation primary response gene induced by IL6. Oncogene. 1990;5(7):1095-1097.
9. Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol. 2002;168(2):554-561.
10. Sareneva T, Julkunen I, Matikainen S. IFNalpha and IL-12 induce IL-18 receptor gene expression in human NK and T cells. J Immunol. 2000;165(4):1933-1938.
11. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519-550.
12. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med. 2007;357(18):1841-1854.
13. Peters-Golden M, Canetti C, Mancuso P, Coffey MJ. Leukotrienes: underappreciated mediators of innate immune responses. J Immunol. 2005;174(2):589-594.
14. Won JS, Im YB, Khan M, Singh AK, Singh I. Involvement of phospholipase A2 and lipoxygenase in lipopolysaccharide-induced inducible nitric oxide synthase expression in glial cells. Glia. 2005;51(1):13-21. (Pubitemid 41059154)
15. Piette J, et al. Multiple redox regulation in NFkappaB transcription factor activation. Biol Chem. 1997;378(11):1237-1245.
16. Paul L, Fraifeld V, Kaplanski J. Evidence supporting involvement of leukotrienes in LPSinduced hypothermia in mice. Am J Physiol. 1999; 276(1 pt 2):R52-R58.
17. Shiratori Y, Tanaka M, Umihara J, Kawase T, Shiina S, Sugimoto T. Leukotriene inhibitors modulate hepatic injury induced by lipopolysaccharide- activated macrophages. J Hepatol. 1990;10(1):51-61.
18. Collin M, et al. Reduction of the multiple organ injury and dysfunction caused by endotoxemia in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. J Leukoc Biol. 2004;76(5):961-970.
19. O'Neill LA, Bowie AG. The family of five: TIRdomain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 2007;7(5):353-364.
20. Medzhitov R, Horng T. Transcriptional control of the inflammatory response. Nat Rev Immunol. 2009;9(10):692-703.
21. Alvarez Y, Municio C, Alonso S, Sanchez Crespo M, Fernandez N. The induction of IL-10 by zymosan in dendritic cells depends on CREB activation by the coactivators CREB-binding protein and TORC2 and autocrine PGE2. J Immunol. 2009;183(2):1471-1479.
22. Tone M, Powell MJ, Tone Y, Thompson SA, Waldmann H. IL-10 gene expression is controlled by the transcription factors Sp1 and Sp3. J Immunol. 2000;165(1):286-291.
23. Bolte S, Cordelieres FP. A guided tour into subcellular colocalization analysis in light microscopy. J Microsc. 2006;224(pt 3):213-232.
24. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009;27:693-733.
25. Bonizzi G, et al. Reactive oxygen intermediate-dependent NF-kappaB activation by interleukin- 1beta requires 5-lipoxygenase or NADPH oxidase activity. Mol Cell Biol. 1999;19(3):1950-1960.
26. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol. 1999;163(1):1-5.
27. Mancuso P, Lewis C, Serezani CH, Goel D, Peters-Golden M. Intrapulmonary administration of leukotriene B4 enhances pulmonary host defense against pneumococcal pneumonia. Infect Immun. 2010;78(5):2264-2271.
28. Harroch S, Gothelf Y, Revel M, Chebath J. 5' upstream sequences of MyD88, an IL-6 primary response gene in M1 cells: detection of functional IRF-1 and Stat factors binding sites. Nucleic Acids Res. 1995; 23(17):3539-3546.
29. Naiki Y, Michelsen KS, Zhang W, Chen S, Doherty TM, Arditi M. Transforming growth factor-beta differentially inhibits MyD88-dependent, but not TRAM- and TRIF-dependent, lipopolysaccharide-induced TLR4 signaling. J Biol Chem. 2005;280(7):5491-5495.
30. Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol. 2006;6(9):644-658.
31. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3(9):651-662.
32. Finbloom DS, Larner AC. Regulation of the Jak/STAT signalling pathway. Cell Signal. 1995;7(8):739-745.
33. Gazit A, Yaish P, Gilon C, Levitzki A. Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem. 1989; 32(10):2344-2352.
34. Lucet IS, et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood. 2006;107(1):176-183.
35. Peres CM, Aronoff DM, Serezani CH, Flamand N, Faccioli LH, Peters-Golden M. Specific leukotriene receptors couple to distinct G proteins to effect stimulation of alveolar macrophage host defense functions. J Immunol. 2007;179(8):5454-5461.
36. Yasukawa H, Sasaki A, Yoshimura A. Negative regulation of cytokine signaling pathways. Annu Rev Immunol. 2000;18:143-164.
37. McCurdy JD, Olynych TJ, Maher LH, Marshall JS. Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J Immunol. 2003;170(4):1625-1629.
38. Lindner SC, Kohl U, Maier TJ, Steinhilber D, Sorg BL. TLR2 ligands augment cPLA2alpha activity and lead to enhanced leukotriene release in human monocytes. J Leukoc Biol. 2009;86(2):389-399.
39. Sanchez-Galan E, et al. Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis. Cardiovasc Res. 2009;81(1):216-225.
40. Hashimoto K, Ichiyama T, Hasegawa M, Hasegawa S, Matsubara T, Furukawa S. Cysteinyl leukotrienes induce monocyte chemoattractant protein-1 in human monocyte/macrophages via mitogen-activated protein kinase and nuclear factor-kappaB pathways. Int Arch Allergy Immunol. 2009;149(3):275-282.
41. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol. 2006;20(5):953-970.
42. Serezani CH, Aronoff DM, Sitrin RG, Peters-Golden M. FcgammaRI ligation leads to a complex with BLT1 in lipid rafts that enhances rat lung macrophage antimicrobial functions. Blood. 2009;114(15):3316-3324.
43. Cheon H, et al. Prostaglandin E2 augments IL-10 signaling and function. J Immunol. 2006;177(2):1092-1100. (Pubitemid 44036612)
44. Gasperini S, et al. Interleukin-10 and cAMP-elevating agents cooperate to induce suppressor of cytokine signaling-3 via a protein kinase A-independent signal. Eur Cytokine Netw. 2002;13(1):47-53.
45. Stevenson NJ, et al. The chemoattractants, IL-8 and formyl-methionyl- leucyl-phenylalanine, regulate granulocyte colony-stimulating factor signaling by inducing suppressor of cytokine signaling-1 expression. J Immunol. 2004;173(5):3243-3249.
46. Liu J. Control of protein synthesis and mRNA degradation by microRNAs. Curr Opin Cell Biol. 2008;20(2):214-221.
47. Sandler H, Stoecklin G. Control of mRNA decay by phosphorylation of tristetraprolin. Biochem Soc Trans. 2008;36(pt 3):491-496.
48. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature. 2006;442(7098):39-44.
49. Tachado SD, et al. MyD88-dependent TLR4 signaling is selectively impaired in alveolar macrophages from asymptomatic HIV+ persons. Blood. 2010;115(17):3606-3615.
50. Chen XS, Sheller JR, Johnson EN, Funk CD. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature. 1994;372(6502):179- 182.
51. Tager AM, et al. Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol. 2003;4(10):982-990.
52. Serezani CH, Perrela JH, Russo M, Peters-Golden M, Jancar S. Leukotrienes are essential for the control of Leishmania amazonensis infection and contribute to strain variation in susceptibility. J Immunol. 2006;177(5):3201-3208.
53. Moore BB, et al. Bleomycin-induced E prostanoid receptor changes alter fibroblast responses to prostaglandin E2. J Immunol. 2005;174(9):5644-5649.
54. Serezani CH, Chung J, Ballinger MN, Moore BB, Aronoff DM, Peters-Golden M. Prostaglandin E2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidase. Am J Respir Cell Mol Biol. 2007;37(5):562-570. (Pubitemid 350058187)